MDGL FY 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$958M+432.1% YoY

Gross Profit

$902M94.1% margin

Operating Income

-$300M-31.3% margin

Net Income

-$288M-30.1% margin

EPS (Diluted)

$-12.85

Cash Flow

Operating Cash Flow

-$190M

Free Cash Flow

-$190M

Stock-Based Comp.

$98M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$657M

Stockholders' Equity

$603M

Cash & Equivalents

$199M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$958M	$180M	+432.1%
Gross Profit	$902M	$174M	+418.8%
Operating Income	-$300M	-$498M	+39.7%
Net Income	-$288M	-$466M	+38.1%